# Abstract

**Background:** Atrial fibrillation (AF) is common and increases stroke risk. Echocardiography is often performed as part of the cardiological evaluation of patients with AF to assist with stroke risk stratification (and hence, decisions on thromboprophylaxis with oral anticoagulants (OACs)). The cost effectiveness of such an approach is unknown.

**Objective:** To estimate the cost-effectiveness of using transthoracic echocardiography (TTE) in helping to make the decision whether to prescribe an OAC in newly diagnosed AF patients.

**Design**: Diagnostic economic modelling analysis.

**Setting:** England & Wales

**Model:** Diagnostic discrete event simulation model.

**Comparisons:** Decisions and consequences following from using TTE in combination with CHADS2, a standard clinical decision tool, were compared with those when using CHADS2 alone.

**Treatments considered:** Warfarin, dabigatran and rivaroxaban were all considered separately as OACs which may be prescribed as a result of the information provided by TTE.

**Population:**  Newly diagnosed AF patients.

**Main outcome measures**: Quality adjusted life years (QALYs) gained, strokes averted, effects on cost and major bleeding events.

**Results:** For patients aged 50 years, using TTE in this way does not appear clinically effective due to the problems of additional overtreatment. For patients aged 65 years, using TTE is more effective but more expensive, with incremental cost-effectiveness ratios (ICERs) which are below conventional willingness to pay thresholds when a newer OAC (rivaroxaban, dabigatran) is being considered, but not warfarin.

**Conclusions:** Using TTE to inform the decision whether to prescribe a newer OAC to newly diagnosed AF patients may be a clinically and cost-effective strategy.

# Introduction

## Background

Atrial fibrillation (AF) is a common arrhythmia affecting around 1-2% of the UK population and is a significant risk factor for stroke.[1] Managing AF effectively is therefore important for reducing mortality and morbidity risks that result from this condition. Oral anticoagulants (OACs) reduce the risk of stroke for AF patients, but can cause major bleeding. [2]

OACs also impose a cost burden, either directly due to drug acquisition costs in the case of newer OAC drugs like dabigatran or rivaroxaban, or indirectly due to monitoring costs in the case of warfarin. In AF patients with an already low stroke risk, prescribing an OAC may not be clinically beneficial, as the mean harm caused by additional major bleeding events exceeds harm averted by preventing strokes. Because of this a range of risk prediction rules are used to identify the higher-risk patients who are likely to benefit from OACs.

A commonly used risk prediction rule for assessing stroke risk is the CHADS2 score, which is an acronym for: (C) congestive heart failure; (H) hypertension; (A) aged 75 years or older; (D) diabetes; prior stroke, transient ischemic attack (S2) [3] In the 2010 European guidelines, if the CHADS­2 score is one point or over, an OAC should be prescribed.

## Transthoracic Echocardiography and the decision problem

This study considers whether additional diagnostic testing of newly diagnosed AF patients with CHADS2 scores of zero could be clinically and cost-effective strategy for appropriately managing their condition. The additional screening is with transthoracic echocardiography (TTE). A CHADS2 score of zero means these patients would conventionally not be prescribed an OAC. However, TTE is able to identify some forms of left atrial abnormality (LA ABN) which indicate that, despite the low CHADS2 score, the patient has a high risk of stroke. [4,5] For these ‘hidden’ high-risk patients, prescribing an OAC is likely to be more beneficial than harmful, and so using TTE in this way improves their AF management. However, as no diagnostic is perfectly accurate, this use of TTE will produce some false positives, resulting in more patients with low stroke risk being prescribed OACs. Also, not all patients who are at higher stroke would be identified (false negatives), and so would still not be treated with OACs. For these reasons, not using TTE in this way (the No TTE Strategy) could lead to better clinical outcomes for these AF patients than using TTE (the TTE Strategy), and so it first needs to be established whether the TTE Strategy is clinically superior to the No TTE Strategy.

If the TTE Strategy is clinically superior, it is then important to estimate whether it is also cost effective, meaning that the ratio of additional costs to additional clinical benefits of the TTE Strategy compared with No TTE strategy is reasonable. The National Institute for Health and Clinical Excellence (NICE) recommends that health benefits be defined in terms of quality-adjusted life years (QALYs), and conventionally applies thresholds ranging from £20,000 per QALY to £30,000 per QALY when deciding whether to recommend a health technology. [6] This modeling study will also use this measure of health benefit and these thresholds.

# Methods

The mathematical model developed estimated the consequences of using TTE to inform the decision whether to prescribe an OAC in a range of patient populations. Eight distinct cohorts were modelled, and separate scenarios were performed for each of three potential OACs: warfarin, dabigatran, and rivaroxaban. These are listed in Table 1. The health economic outcome of interest is the quality adjusted life year (QALY). [7] A UK perspective is adopted, with costs incurred by the patient or wider society not considered. Standard NICE discount rates for utilities and costs of 3.5% per annum are used. [8] A lifetime horizon is adopted, and in order to incorporate the effect of uncertainty on predicted outcomes, a probabilistic model is used, meaning that where possible model parameter estimates are drawn from distributions rather than assumed to be fixed values.

## Scenarios included

Warfarin, rivaroxaban, and dabigatran are each recommended in patients with different clinical characteristics. Warfarin is recommended in patients with a CHADS2 score of one or more; the recent NICE recommendations for rivaroxaban are equivalent to stating that patients with a CHADS2 score of one or more should receive it; and recent NICE recommendations for dabigatran are equivalent to stating that patients with a CHADS2 score of one or more should receive it if they are also aged 65 years or more. [9,10] The purpose of this paper is not to identify the most appropriate OAC, which is a matter of clinician judgement, but to see if the use of TTE is clinically effective and cost-effective given OAC under consideration. The scenarios in which a TTE may affect the OAC decision are described in Table 1.

[Table 1 about here]

## Model Overview

An overview of the model is presented in Figure 1. The model comprises a short-term diagnostic stage and a long-term patient outcome stage. In the short-term stage the clinical characteristics of a hypothetical patient are generated. Whether or not an LA ABN was identified and hence an OAC was prescribed is additionally determined. In the long-term simulation the patient’s clinical outcomes are simulated. Over the patient lifetime the patient may experience a stroke or major bleeding event, both of which could cause death; patients may also die from another cause. Each of these events has associated cost and utility implications. By simulating the outcomes for a large number of patients, the mean costs and mean QALYs for both the TTE Strategy, where TTE is used as described above, and the No TTE strategy, where TTE is not used for this purpose, are estimated. From these the incremental cost effectiveness ratio (ICER) of including TTE in the diagnostic package.

In the No TTE Strategy, none of the patients with LA ABN would be treated with the OAC. In the comparator strategy, a percentage of these patients with LA ABN would receive the OAC due to TTE correctly identifying LA ABN, dependent on sensitivity of TTE. However, when specificity is less than perfect a proportion of patients without LA ABN would also receive it.

In the short-term diagnostic stage of the model the population are divided into true positives (TPs), true negatives (TNs), false positives (FPs) and false negatives (FNs). The relative size of each of the four groups is a function of the proportion of the population with LA ABN, referred to here as the true proportion high risk (TPHR), and the sensitivity and specificity of the diagnostic technology. These are defined as follows:

* Proportion of TPs = TPHR x sensitivity;
* Proportion of TNs = (1 –TPHR) x specificity;
* Proportion of FPs = (1 – TPHR) x (1 – specificity);
* Proportion of FNs = TPHR x (1 – sensitivity).

Within the context of the model, No TTE strategy should be considered to have a sensitivity of zero and a specificity of one, meaning for this strategy the population mix comprises TPHR false negatives and (1 - TPHR) true negatives.

## Modelling long-term events

Prescribing an OAC reduces the risk of stroke, but increases risk of a potentially fatal major bleeding event. Three mutually exclusive outcomes could result from a stroke: death; a dependent state; and an independent state. Each outcome has different health related quality of life (HRQoL), probabilities and costs. Similarly, three mutually exclusive outcomes could result from a major bleeding event: death; an intracranial (IC) bleeding event; or a non-intracranial (NIC) bleeding event (assumed to be a gastrointestinal bleed). The severity of an IC bleed can vary substantially, and this variation of outcomes was itself simulated using data based on outcomes categorized by Glasgow Outcome Scale (GOS) score following traumatic brain injury. The full methodology used to produce these estimates is presented elsewhere. [11]

The model is dynamic and updated when events occur that affect an individual’s stroke or bleed risk. Examples of such events are: experiencing a stroke; withdrawal of an OAC following a major bleed; and reaching 75 years of age, which increases the CHADS2 score by one point. It was assumed that if a patient experiences a stroke and is not already taking an OAC, they are prescribed OACs, provided they have not experienced a previous bleeding episode. If a patient suffers a severe intracranial haemorrhage (Glasgow Outcome Scale category 2) as a result of taking OACs, their life expectancy was reduced to a maximum of 3.6 years with no QALY gain. [12] Additionally, the risk of a major bleeding event when taking dabigatran (150mg twice daily) was also assumed to change at the age of 75, as indicated by recent evidence comparing dabigatran with warfarin. [13]

## Data sources used in model

A full list of the information used to populate the parameters in the model, including event risks, costs and utilities, is presented in Table 2.

## Estimating cost effectiveness

The adoption decision, the strategy that is deemed most cost effective, is calculated from the mean values of the costs and the QALYs of each strategy. Scatterplots of estimates produced by the PSA provide an indication of uncertainty surrounding the adoption decision. A point in the north-west quadrant indicates that the TTE Strategy is both more costly and less effective than the No TTE Strategy, and so ruled out by dominance. A point in the north-east quadrant indicates that the TTE Strategy is both more expensive and more clinically effective than the No TTE Strategy, and consideration is given to whether the ICER, the ratio of additional cost to additional benefit, is below a maximum acceptable incremental cost effectiveness ratio (MAICER). NICE often uses MAICERs between £20 000 per QALY and £30 000 per QALY. [6] Scatterplots where the scatter covers more than one quadrant indicate some level of decision uncertainty, as different quadrants suggest different decisions. [14]

## Deterministic sensitivity analyses

Sensitivity analyses were also undertaken on the joint uncertainty in the sensitivity and specificity of TTE in detecting LA ABN. The results for the joint uncertainty for three scenarios are presented in the main article. The remainder of these analyses are presented in the online appendix.

# Results

Table 3 presents some summary statistics of simulated patient outcomes for the TTE Strategy and the No TTE Strategy, where the patient population is of 65 year old females with an initial CHADS2 score of 0, and the OAC is either warfarin, rivaroxaban, or dabigatran. Figure 2 show the PSA scatterplots where the OAC is either warfarin (a), rivaroxaban (b), or dabigatran (c). Table 4 shows the mean costs and mean QALYs of the No TTE Strategy and the TTE Strategy, and the ICER comparing these strategies. Results for other patient groups are included in the appendix.

Table 3 indicates that, irrespective of the OAC, using TTE in this way reduces the proportion of deaths caused by stroke, but increases the proportion of deaths caused by bleed. On average, the scenarios not using TTE are estimated to result in a lower rate of dependent and independent strokes, and a higher rate of major bleeding events, including intracranial haemorrhages (ICHs). For all OAC scenarios, the number of life years is estimated to be slightly greater when strategy incorporating TTE is used compared to the strategy without TTE, but these differences are relatively small.

Figure 2 and Table 4 both suggest that the cost-effectiveness of the TTE strategy compared with the no TTE strategy depends on the OAC which would be prescribed. Where the OAC is warfarin (Table 4a), the ICER comparing the two strategies is almost £40 000 per QALY; where the OAC rivaroxaban (Table 4b), the ICER reduces to around £23 000 per QALY, and where the OAC is dabigatran (Table 4c), the ICER reduces further to around £12 000 per QALY.

## Deterministic sensitivity analyses

Table 6 shows how the mean ICER estimated depends on the sensitivity and specificity of the technology, assuming all other values are held at their mean levels, where the OAC is either a) warfarin, b) rivaroxaban, or c) dabigatran. If TTE had perfect sensitivity and specificity, then the additional cost per QALY is estimated to range from around £1,800/QALY for warfarin (a) to £1,100/QALY for dabigatran (c). However, due to the less than perfect specificity of TTE, estimated to be around 0.35, and the increased number of false positives predicted to be treated as a result of this, the ICERs increase becoming around £27,000-£59,000/QALY for warfarin (a), £18,000-£29,000 for rivaroxaban (b), and £10,000-£14,000 for dabigatran (c). [5] As the ICER is a ratio, and the absolute differences in QALYs between strategies with and without TTE are small, the ICERs are shown to be highly sensitive to the values of sensitivity and specificity assumed for some scenarios.

## Overview of results for other scenarios

The full results for all 10 scenarios considered are presented in the online appendix. A brief summary, indicating whether the results suggest TTE appears cost-effective at MAICERs of £20,000 /QALY or £30,000/QALY, is shown in Table 7. These results suggest that the addition of TTE to help make the decision whether to prescribe an OAC appears more expensive and less effective than not using TTE in patients aged 50 years. In patients aged 65 years, the strategy using TTE appears cost-effective and conventional willingness-to-pay thresholds of between £20,000 and £30,000/QALY for dabigatran, and possibly for rivaroxaban. The cost-effectiveness of the strategy appears slightly more favourable for female than for male patients, but the choice of OAC and patient age appear to have much greater influence.

# Discussion

Prior to producing this model, a systematic literature review was conducted to identify, summarise and appraise existing economic studies for evaluating the cost-effectiveness of TTE in patients with AF. This review identified no economic evaluations of the use of TTE in AF patients, so it is believed that this is the first.

The model has a range of limitations and a number of assumptions have been made within the modelling. For example, only the CHADS2 clinical risk prediction tool was used as the baseline strategy. An alternative to this tool is CHA2DS2-VASc, which is considered to be better at distinguishing low risk from very low risk patients, and is the only such tool recommended in the 2012 focused update of the ESC guidelines. [3,15–17] CHA2DS2-VASc was not used in these analyses as the recent NICE recommendations for the use of dabigatran and rivaroxaban both map onto specific CHADS2 risk scores, but not specific CHA2DS2-VASc risk scores. [9,10] The dose of dabigatran was fixed at 150mg twice daily, rather than allowing some patients to receive a lower dose of 110mg twice daily. The stroke risk associated with patients with LA ABN was assumed not to change as a patient ages; ideally differential rates by age or by the number (and type) of abnormalities would be used but these data were not identified.

Within the study used to derive the sensitivity and specificity of TTE, transoesophageal echocardiography (TOE), was assumed to be a perfect gold standard, and so our model also made this assumption. [5] Using TOE as the gold standard, TTE was estimated to have a very high sensitivity but a specificity of only around 35 %. Within this model, this low specificity corresponds to an increased proportion of ‘false positives’ being included in the patient population mix, and so TTE results in a considerable number of people effectively experiencing comparable risks of bleed without the increased benefits in terms of stroke risk reduction estimated in patients with a higher risk of stroke. If TTE were found to be superior to TOE at identifying certain types of LA ABN which expose patients to increased stroke risks, then the true benefits of TTE in improving patient management would be underestimated. The study used to derive sensitivity and specificity was relatively small, of fewer than 400 patients, and also formed the basis of our estimates of the TPHR. [5] This has made the assessment of the benefits of TTE uncertain. A further limitation is that the risk of death unrelated to bleeding or stroke events was taken from lifetables and were not adjusted for the probability of bleeding or stroke mortality. [18]

A key uncertainty is whether there are incidental benefits that are accrued from a TTE other than identifying some forms of LA ABN. If these exist, and produce even small net QALY gains (> 0.0033) then TTE would be cost effective in all scenarios, assuming a cost of £66 per test. [19] Assuming a higher test cost applies (£425) then the QALY gain required of incidental benefits increases to approximately 0.02. [19] As Table 6b indicates, the structural sensitivity analyses for this scenario indicate that even a diagnostic strategy with a joint sensitivity of one and specificity of zero (i.e. prescribing everyone with the OAC) may be cost effective compared with treating no-one. The implications of this result require further research.

## Implications for Research

For some scenarios the cost effectiveness estimates generated by the model depend heavily on sensitivity and specificity estimates, as well as the true proportion of genuinely high risk (LA ABN that can be detected by TTE) patients in this sub-population of apparently ‘low risk’ patients. The model depends strongly on data reported in a single, relatively small study conducted outside of the UK, and so may misrepresent the true values of these parameters. Having a more robust source of evidence for these parameters, with direct relevance to England and Wales, is likely to significantly improve the accuracy of the mathematical models.

Additional research that would improve the validity of the model include identifying any incidental net benefits to the management of newly diagnosed AF patient that could result from routine screening with TTE following initial diagnosis.

## Implications for clinical practice

Should TTE be recommended for those patients with CHADS2 scores of zero points, there will be an increase in the number of TTEs performed. This is unlikely to place a great burden on the majority of hospitals who are likely to have staff trained in the use of TTE machines. It is likely that additional bed days are made available due to the reduction in stroke following appropriate management, although there is likely to be an increase in bleed related admissions.

## Conclusion

This paper presented the results of mathematical models which simulated the effects of using TTE to help make the decision whether to prescribe an OAC in a range of patients with AF. It was estimated that when rivaroxaban or dabigatran is the OAC of choice then it appears cost-effective to use TTE in patients aged 65 years; when warfarin is the OAC of choice, then the addition of TTE does not appear cost-effective at standard willingness to pay thresholds of either £20,000 per QALY or £30,000/QALY. These results suggest that if considering prescribing a newer OAC, it may be both clinically effective and cost effective to use TTE to help inform the decision.

# References

1 Go AS, Hylek EM, Phillips KA, *et al.* Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA : the journal of the American Medical Association* 2001;**285**:2370–5.

2 Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. *American heart journal* 2010;**159**:340–347.e1.

3 Camm AJ, Kirchhof P, Lip GY, *et al.* Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;**31**:2369–429.

4 Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. *Ann Intern Med* 1998;**128**:639–47.

5 Providencia R, Botelho A, Trigo J, *et al.* Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters. *Europace* 2012;**14**:36–45.

6 NICE. Guide to the methods of technology appraisal. 2008.http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf

7 Pliskin JS, Shepard DS, Weinstein MC. Utility Functions for Life Years and Health Status. *Operations Research* 1980;**28**:206–24.

8 NICE. Guide to the methods of technology appraisal. NICE methods guide. 2008;:80.

9 NICE. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE technology appraisal guidance 256. 2012.http://www.nice.org.uk/nicemedia/live/13746/59295/59295.pdf (accessed 28 Sep2012).

10 NICE. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. NICE technology appraisal guidance 249. 2012.http://www.nice.org.uk/nicemedia/live/13677/58470/58470.pdf (accessed 28 Sep2012).

11 Simpson EL, Stevenson MD, Scope A, *et al.* Echocardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic evaluation. 2012.

12 PVS TM-STF on. Medical aspects of the persistent vegetative state: second of two parts. *The New England Journal of Medicine* 1994;**330**.http://www.nejm.org/doi/full/10.1056/NEJM199406023302206

13 Eikelboom JW, Wallentin L, Connolly SJ, *et al.* Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation* 2011;**123**:2363–72.

14 Drummond MF, Schulpher MJ, Torrance GW, *et al.* *Methods for the Economic Evaluation of Health Care Programmes*. Third Edit. Oxford: : OUP 2005.

15 Camm AJ, Lip GYH, De Caterina R, *et al.* 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation \* Developed with the special contribution of the European Heart Rhythm Association. *European heart journal* Published Online First: 24 August 2012. doi:10.1093/eurheartj/ehs253

16 Lip GY, Nieuwlaat R, Pisters R, *et al.* Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;**137**:263–72.

17 Olesen JB, Lip GYH, Hansen ML, *et al.* Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ* 2011;**342**:d124–d124.

18 ONS. Interim Life Tables. 2011;**2012**.http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Interim+Life+Tables

19 DoH. NHS Reference Costs 2009-2010. 2011;**2012**.http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\_123459

20 Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *European heart journal* Published Online First: 13 January 2012. doi:10.1093/eurheartj/ehr488

21 Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. *Thrombosis research* 2006;**118**:321–33.

22 Patel MR, Mahaffey KW, Garg J, *et al.* Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. *New England Journal of Medicine* 2011;**365**:883–91.

23 Rivero-Arias O, Ouellet M, Gray A, *et al.* Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome. *Medical Decision Making* 2010;**30**:341–54.

24 Simpson EL, Stevenson MD, Rawdin A, *et al.* Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis. *Health Technology Assessment* 2009;**13**. doi:10.3310/hta13020

25 Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research* 2010;**13**:509–18.

26 NICE. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: Final appraisal determination. 2011;**2012**.http://www.nice.org.uk/nicemedia/live/12225/56899/56899.pdf

27 Group LND. A briefing paper on Dabigatran and Rivaroxaban: What we know so far... 2012;**2012**.http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/A-briefing-paper-on-dabigatran-and-rivaroxaban/

28 BNF. Warfarin. 2011;**2012**.https://mail.google.com/mail/u/1/#inbox/134f06255f3f63de

29 Sandercock P, Berge E, Dennis M, *et al.* A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. *Health Technology Assessment* 2002;**6**.

30 NHS. National Stroke Strategy Impact Assessment. 2007;**2012**.http://www.dh.gov.uk/prod\_consum\_dh/groups/dh\_digitalassets/documents/digitalasset/dh\_081054.pdf

31 Curtis L. Unit Costs of Health and Social Care 2010. Kent: 2010.



Figure 1 Graphical representation of the mathematical model

|  |  |  |  |
| --- | --- | --- | --- |
| **CHADS2 score** | **Prescribe dabigatran** | **Prescribe warfarin** | **Prescribe rivaroxaban** |
| 0 | No | No | No |
| 1 | Yes (age 65 or over) | Yes (or aspirin) | Yes |
| 2 or more | Yes | Yes | Yes |
| **Cohorts simulated** | **Scenarios considered for dabigatran** | **Scenarios considered for warfarin** | **Scenarios considered for rivaroxaban** |
| Males, age 50, CHADS2 score of zero | No † | Yes | Yes |
| Females, age 50, CHADS2 score of zero | No † | Yes | Yes |
| Males, age 65, CHADS2 score of zero | Yes | Yes | Yes |
| Females, age 65, CHADS2 score of zero | Yes | Yes | Yes |
| \* Patient would automatically receive treatment.  † OAC not permitted under NICE guidance | | | |

Table 1 Simplified OAC indications by OAC, and patient cohorts run for each OAC

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Category** | **Description** | **References** |
| **Risks/Probabilities** | Death from other causes | Nonparametric | UK Lifetables. [18] |
| Sensitivity and Specificity of TTE in detecting LA ABN | Jointly estimated from Dirichlet distribution  (FN, TP, TN, FP) =  (5, 87, 83, 159) | Table 2 of Providencia et al 2012 [5] |
| Proportion of patients with LA ABN | Beta(2.5, 22.5) for CHADS2  Beta(0.5, 11.5) for CHA2DS2-VASc  (Both with prior of 0.5 added to both cell counts.) | Table 2 of Providencia et al 2012 [5] |
| Annual stroke risk by CHADS2 score | Annual risks (95% Credible intervals) by CHADS2 were reported as follows:  0.6% (0.5% to 0.7%) for CHADS2=0  3.0% (2.9% to 3.2%) for CHADS2=1  4.2% (4.0% to 4.4%) for CHADS2=2  7.1% (6.7% to 7.5%) for CHADS2=3  11.1% (10.4% to 11.8%) for CHADS2=4 | Friberg 2012[20] |
| Annual stroke risk in those with LA ABN | In the initial study four out of 50 patients with identified LA ABN had a stroke. This was used to produce a mean stroke rate of 8.0% and bootstrapped 95% CrIs of 7.2% to 8.2% | Stroke Prevention 1988 [4] |
| Relative risk (RR) of stroke in patients receiving dabigatran. | Indirect comparison simulation approach. One thousand simulated values from a lognormal distribution representing the RR of warfarin compared with placebo were multiplied by 1000 simulated values from a lognormal distribution comparing dabigatran with warfarin, to produce 1000 estimates of the RR of dabigatran compared with placebo. Mean RRs and 95% CIs/CrIs are shown below:  Reported RR warfarin vs. placebo: 0.33 (0.24 to 0.45)  Reported RR dabigatran vs. warfarin: 0.66 (0.53 to 0.82)  Derived RR dabigatran vs. placebo: 0.22 (0.15 to 0.32) | Lip et al 2006 for RR of warfarin compared with placebo [21]  Eikelboom et al 2011 for RR of dabigatran compared with warfarin[13] |
| Annual major bleeding risk for patients receiving dabigatran | Stratified by age. Credible interval calculated using simulation approach. Annual risk reported separately for people under 75 years, and people aged 75 years or older. Credible intervals were calculated by assuming sample sizes of 3618 for people aged under 75 years and 2419 for people aged 75 years or older, then sampling repeatedly and taking the values 2.5% and 97.5% of the way along the distributions. The central estimates (95% CrIs) are as follows:  Under 75: 2.1% (1.7 to 2.6%)  75 and older: 5.1% (4.2% to 6.0%) | Eikelboom et al 2011 [13] |
| Relative risk (RR) of stroke in patients receiving warfarin | Reported RR warfarin vs. placebo: 0.33 (0.24 to 0.45) | Lip et al 2006 [21] |
| Annual major bleeding risk for patients receiving warfarin | Stratified by age. Credible interval calculated using simulation approach. Annual risk reported separately for people under 75 years, and people aged 75 years or older. Credible intervals were calculated by assuming sample sizes of 3618 for people aged under 75 years and 2419 for people aged 75 years or older, then sampling repeatedly and taking the values 2.5% and 97.5% of the way along the distributions. The central estimates (95% CrIs) are as follows:  Under 75: 3.4% (2.5 to 3.6%)  75 and older: 4.4% (3.6% to 5.2%) | Eikelboom et al 2011 [13] |
| Relative risk (RR) of stroke in patients receiving rivaroxaban | Indirect comparison simulation approach. One thousand simulated values from a lognormal distribution representing the RR of warfarin compared with placebo were multiplied by 1000 simulated values from a lognormal distribution comparing dabigatran with warfarin, to produce 1000 estimates of the RR of dabigatran compared with placebo. Mean RRs and 95% CIs/CrIs are shown below:  Reported RR warfarin vs. placebo: 0.33 (0.24 to 0.45)  Reported RR Rivaroxaban vs. warfarin: 0.88 (0.74 to 1.03)  Derived RR Rivaroxaban vs. placebo: 0.30 (0.20 to 0.41) | Lip et al 2006 for RR of warfarin compared with placebo [21]  Patel et al 2011 for RR of rivaroxaban compared with warfarin [22] |
| Annual major bleeding risk for patients receiving rivaroxaban | The annual risk of bleeding given rivaroxaban was estimated indirectly by combining estimates of the risk of bleed given warfarin compared with placebo with estimates of the risk of bleed given rivaroxiban compared with warfarin. The central estimates (95% CrIs) were estimated to be as follows:  Under 75: 3.2% (2.5% to 4.0%)  75 or older: 4.6% (3.6% to 5.7%) | Eikelboom et al 2011 [13]  Patel et al 2011 [22] |
| Outcome following stroke | Simulation & mapping based approach described in an upcoming report.  The proportion dying of a stroke (95% CrI) was estimated to be 0.25 (0.23 to 0.27); the proportion in an independent state was estimated to be 0.56 (0.52 to 0.59); and the proportion in an dependent state following a stroke was estimated to be 0.19 (0.16 to 0.23). | Method described in report using results published in Rivero-Arias et al 2010 [23] |
| Outcome following a major bleeding event | Previous estimates | Simpson et al 2010 [24] |
| **Utilities** | Baseline utilities by age and gender | Regression based approach, described in full in the reference. | Ara et al 2010 [25] |
| Utility multiplier following stroke, utility multiplier following major non-fatal intracranial bleed | Simulation & mapping based approach described in an upcoming report.  Utility multipliers (95% CrIs) were estimated to be 0.822 (0.819 to 0.824) for an independent state following a stroke, and 0.482 (0.477 to 0.487) for a dependent state following a stroke. | Method described in report results published in  Rivero-Arias et al 2010 [23] |
| **Costs** | Annual cost of dabigatran | £920. A fixed cost was assumed. | NICE FAD, 2011 [26] |
| Annual cost of rivaroxaban | £767. A fixed cost was assumed. | London New Drugs Group [27] |
| Annual cost of warfarin | £252 to £259 including monitoring costs. A uniform distribution was assumed. | BNF [28] |
| Cost of TTE | £66 | NHS Reference Costs [19] |
| Cost of death due to stroke | £7,019 (95% CrI £6,975 to £7,064) | Sandercock et al 2002 [29] |
| Costs in stroke survivors | Various. Differing according to dependent and independent states. Subdivided into one-off and continuing costs. Estimates (95% CrIs) are as follows:  Dependent stroke, one-off costs: £2830 (£2708 to £2952)  Dependent stroke, continuing annual cost: £6386 (£5749 to £7023)  Independent stroke, one-off costs: £542 (£513 to £571)  Independent stroke, continuing annual cost: £3195 (£2871 to £3518) | NHS Reference Costs [19]  NHS Stroke Strategy Impact Assessment [30]  Unit Costs of Health and Social Care 2010 [31] |
| Costs of fatal bleed | Assumed identical to costs of death due to stroke | |
| Costs of nonfatal bleed | Major bleeds subdivided into gastrointestinal (GI) and intracranial (IC). GI bleeds were assumed to incur a one-off cost but no continuing costs. The one-off cost (95% CrI) was £1261 (£1212 to £1310).  For IC bleeds, the costs depended on the Glasgow Outcome Scale (GOS) level of disability that they cause, from GOS 2 (most severe) to GOS 5 (least severe).  The one-off costs (95% CrIs) used were as follows:  GOS 2: £46785 (£40895 to £53250)  GOS 3: £10096 (£8849 to £11363)  GOS 4: £27419 (£22582 to £32964)  GOS 5: £1261 (£1211 to £1309)  GOS 4 and GOS 5 states were assumed not to have ongoing costs. The ongoing annual costs (95% CrIs) of the other states were as follows:  GOS 2: £50047 (£49645 to £50343)  GOS 3: £33949 (£33843 to £33969) | NHS Reference Costs [19] |

Table 2 Parameters used in model

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | |  |  | ***Cause of Death (%)*** | | | ***Average Number of Events*** | | | | | ***Strategy*** | **Life Years** | **Stroke** | **Bleed** | **Other** | **Dependent Strokes** | **Independent Strokes** | **ICH** | **NICH** | | **Without TTE** | 17.132 | 9.0 | 0.9 | 90.2 | 0.087 | 0.192 | 0.007 | 0.052 | | **With TTE** | 17.204 | 8.0 | 1.3 | 90.7 | 0.078 | 0.172 | 0.010 | 0.079 | |
| 1. warfarin |
| |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | |  |  | ***Cause of Death (%)*** | | | ***Average Number of Events*** | | | | | ***Strategy*** | **Life Years** | **Stroke** | **Bleed** | **Other** | **Dependent Strokes** | **Independent Strokes** | **ICH** | **NICH** | | **Without TTE** | 19.460 | 10.5 | 1.1 | 88.4 | 0.103 | 0.223 | 0.009 | 0.066 | | **With TTE** | 19.554 | 9.4 | 1.6 | 89.0 | 0.093 | 0.201 | 0.012 | 0.096 | |
| 1. rivaroxaban |
| |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | |  |  | ***Cause of Death (%)*** | | | ***Average Number of Events*** | | | | | ***Strategy*** | **Life Years** | **Stroke** | **Bleed** | **Other** | **Dependent Strokes** | **Independent Strokes** | **ICH** | **NICH** | | **Without TTE** | 19.485 | 10.2 | 1.1 | 88.7 | 0.099 | 0.220 | 0.009 | 0.066 | | **With TTE** | 19.598 | 9.0 | 1.6 | 89.4 | 0.089 | 0.195 | 0.012 | 0.097 | |
| 1. dabigatran |

Table 3 Mean simulated clinical experiences of cohorts of 65 year old females with an initial CHADS2 score of zero, when TTE is either used or not used to inform the decision whether to prescribe either a) warfarin, b) rivaroxaban, or c) dabigatran.

TTE: transthoracic echocardiography; LA ABN- Left atrial abnormality; ICH = intracranial haemorrhage; NICH = non-intracranial haemorrhage

Figure 2 Probabilistic sensitivity analysis (PSA) scatterplots of using transthoracic echocardiography to inform the decision whether to prescribe either warfarin, rivaroxaban, or dabigatran to 65 year old females with atrial fibrillation and an CHADS2 score of zero.

|  |  |  |
| --- | --- | --- |
| X:\BMJ Echo AF Manuscript\S8\scatter_W_65_F.jpeg | X:\EchoAF\R\Figures\R_65_0_F__PSA.jpeg | X:\EchoAF\R\Figures\D_65_0_F__PSA.jpeg |
| 1. warfarin | 1. rivaroxaban | 1. dabigatran |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  | | --- | --- | --- | |  | **Mean Cost (£)** | **Mean QALY** | | **Without TTE** | 1 974 | 9.94 | | **With TTE** | 3 106 | 9.97 | | ICER (95% CrIs) | 39 569 (39 374 to 39 839) £/QALY | | |
| 1. warfarin |
| |  |  |  | | --- | --- | --- | |  | **Mean Cost (£)** | **Mean QALY** | | **Without TTE** | 1 955 | 9.95 | | **With TTE** | 3 039 | 9.99 | | ***ICER (95% CrIs)*** | 22 751 (22 681 to 22 844) £/QALY | | |
| 1. rivaroxaban |
| |  |  |  | | --- | --- | --- | |  | **Mean Cost (£)** | **Mean QALY** | | **Without TTE** | 1 942 | 9.95 | | **With TTE** | 2 946 | 10.01 | | ***ICER (95% CrIs)*** | 12 314 (12 290 to 12 348) £/QALY | | |
| 1. dabigatran |

Table 4 Estimated mean costs and mean QALYs of using or not using TTE to make the decision to prescribe either a) warfarin, b) rivaroxaban, or c) dabigatran for 65 year old females with an initial CHADS2 score of zero. ICER: incremental cost effectiveness ratio. CrIs: Credible intervals; calculated using a jacknifing procedure.

Table 6 Illustration of the effect of different levels of sensitivity and specificity on ICER of TTE compared with no TTE in cohorts of female patients aged sixty five, and with an initial CHADS2 score of zero, in making the decision whether to prescribe a) warfarin, b) rivaroxaban, or c) dabigatran. The four cells with sensitivity and specificity values closest to the empirical values are underlined. (Amounts in £1000 / QALY; >99; Over £99,000/QALY; D: Dominated)

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | *Specificity* | | | | | | | | | | |
|  | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** |
| *Sensitivity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ |
| **0.1** | D | D | D | D | D | D | D | D | D | >99 | 8.1 |
| **0.2** | D | D | D | D | D | D | D | D | >99 | 24.4 | 4.6 |
| **0.3** | D | D | D | D | D | D | D | >99 | 39.9 | 12.9 | 3.4 |
| **0.4** | D | D | D | D | D | D | >99 | 54.7 | 21.0 | 9.0 | 2.8 |
| **0.5** | D | D | D | D | D | >99 | 68.9 | 28.8 | 14.4 | 7.0 | 2.5 |
| **0.6** | D | D | D | D | >99 | 82.4 | 36.5 | 19.8 | 11.1 | 5.8 | 2.3 |
| **0.7** | D | D | D | >99 | 95.4 | 44.1 | 25.1 | 15.2 | 9.1 | 5.0 | 2.1 |
| **0.8** | D | D | >99 | >99 | 51.4 | 30.3 | 19.2 | 12.4 | 7.8 | 4.5 | 2.0 |
| **0.9** | D | >99 | >99 | 58.6 | 35.4 | 23.2 | 15.7 | 10..6 | 6.9 | 4.1 | 1.9 |
| **1** | >99 | >99 | 65.7 | 40.5 | 27.1 | 18.9 | 13.3 | 9.2 | 6.1 | 3.7 | 1.8 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***b)*** | | *Specificity* | | | | | | | | | | |
|  | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** |
| *Sensitivity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ |
| **0.1** | D | D | D | D | D | D | D | D | D | 77.0 | 7.3 |
| **0.2** | D | D | D | D | D | D | D | D | 65.3 | 17.4 | 4.1 |
| **0.3** | D | D | D | D | D | D | >99 | 61.4 | 23.9 | 10.1 | 3.0 |
| **0.4** | D | D | D | D | D | >99 | 59.5 | 28.4 | 14.8 | 7.3 | 2.4 |
| **0.5** | D | D | D | D | >99 | 58.3 | 31.7 | 18.6 | 10.9 | 5.8 | 2.1 |
| **0.6** | D | D | >99 | >99 | 57.5 | 34.2 | 21.8 | 14.0 | 8.7 | 4.8 | 1.9 |
| **0.7** | D | >99 | >99 | 57.0 | 36.3 | 24.4 | 16.7 | 11.3 | 7.3 | 4.2 | 1.7 |
| **0.8** | >99 | 93.2 | 56.6 | 37.9 | 26.6 | 19.0 | 13.6 | 9.5 | 6.3 | 3.7 | 1.6 |
| **0.9** | 87.0 | 56.2 | 39.3 | 28.5 | 21.1 | 15.6 | 11.5 | 8.2 | 5.6 | 3.4 | 1.5 |
| **1** | 56.0 | 40.4 | 30.1 | 22.9 | 17.5 | 13.3 | 10.0 | 7.3 | 5.0 | 3.1 | 1.5 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***c)*** | | *Specificity* | | | | | | | | | | |
|  | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** |
| *Sensitivity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ |
| **0.1** | D | D | D | D | D | D | D | D | >99 | 28.3 | 6.2 |
| **0.2** | D | D | D | D | D | >99 | >99 | 46.8 | 23.8 | 11.2 | 3.3 |
| **0.3** | D | D | >99 | >99 | 99.6 | 57.0 | 35.4 | 22.2 | 13.4 | 7.1 | 2.4 |
| **0.4** | >99 | >99 | 97.7 | 63.5 | 43.6 | 30.6 | 21.5 | 14.7 | 9.5 | 5.3 | 1.9 |
| **0.5** | 96.6 | 67.9 | 49.8 | 37.2 | 28.0 | 21.0 | 15.5 | 11.0 | 7.4 | 4.3 | 1.6 |
| **0.6** | 54.5 | 42.5 | 33.5 | 26.4 | 20.7 | 16.1 | 12.2 | 8.9 | 6.1 | 3.6 | 1.4 |
| **0.7** | 38.1 | 31.0 | 25.3 | 20.5 | 16.5 | 13.0 | 10.1 | 7.5 | 5.2 | 3.1 | 1.3 |
| **0.8** | 29.3 | 24.5 | 20.4 | 16.8 | 13.7 | 11.0 | 8.6 | 6.4 | 4.5 | 2.8 | 1.2 |
| **0.9** | 23.9 | 20.2 | 17.1 | 14.3 | 11.8 | 9.5 | 7.5 | 5.7 | 4.0 | 2.5 | 1.1 |
| **1** | 20.1 | 17.3 | 14.7 | 12.4 | 10.3 | 8.4 | 6.7 | 5.1 | 3.6 | 2.3 | 1.1 |

Table 7 Qualitative summary of results of all 10 scenarios. ICERs presented to nearest £1,000/QALY. QALY: Quality Adjusted Lifeyear. ICER: Incremental Cost Effectiveness Ratio. NA: Not applicable. OAC: Oral anticoagulant. TTE: Transthoracic echocardiography. Simple Dominance: TTE strategy is more expensive and less effective than no TTE strategy.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Age | Gender | OAC | ICER of TTE compared with no TTE strategy | TTE optimal | |
| At £20,000 / QALY | At £30,000 / QALY |
| 50 | male | warfarin | NA: Simple dominance | No | No |
| 50 | female | warfarin | NA: Simple dominance | No | No |
| 65 | male | warfarin | £67,000/QALY | No | No |
| 65 | female | warfarin | £40,000/QALY | No | No |
| 50 | male | rivaroxaban | NA: Simple dominance | No | No |
| 50 | female | rivaroxaban | NA: Simple dominance | No | No |
| 65 | male | rivaroxaban | £30,000/QALY | No | Borderline[[1]](#footnote-1) |
| 65 | female | rivaroxaban | £23,000/QALY | No | Yes |
| 65 | male | dabigatran | £15,000/QALY | Yes | Yes |
| 65 | female | dabigatran | £12,000/QALY | Yes | Yes |

# Appendix

## Sensitivity and Specificity tables

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***W\_50*** | | *Specificity* | | | | | | | | | | | | ***0\_M*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Sensitivity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | D | D | 8.4 | | **0.2** | D | D | D | D | D | D | D | D | D | D | 5.7 | | **0.3** | D | D | D | D | D | D | D | D | D | 70.7 | 4.9 | | **0.4** | D | D | D | D | D | D | D | D | D | 26.2 | 4.4 | | **0.5** | D | D | D | D | D | D | D | D | >99 | 17.1 | 4.2 | | **0.6** | D | D | D | D | D | D | D | D | 65.6 | 13.1 | 4.0 | | **0.7** | D | D | D | D | D | D | D | D | 35.0 | 10.9 | 3.8 | | **0.8** | D | D | D | D | D | D | D | >99 | 24.5 | 9.5 | 3.8 | | **0.9** | D | D | D | D | D | D | D | 63.9 | 19.2 | 8.5 | 3.7 | | **1** | D | D | D | D | D | D | >99 | 40.2 | 16.0 | 7.8 | 3.6 | |
| 1. W\_50\_0\_M |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***W\_65*** | | *Specificity* | | | | | | | | | | | | ***0\_M*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Sensitivity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | D | D | 8.9 | | **0.2** | D | D | D | D | D | D | D | D | D | 29.8 | 4.9 | | **0.3** | D | D | D | D | D | D | D | D | 62.8 | 13.9 | 3.6 | | **0.4** | D | D | D | D | D | D | D | >99 | 25.0 | 9.3 | 2.9 | | **0.5** | D | D | D | D | D | D | >99 | 38.8 | 15.9 | 7.1 | 2.5 | | **0.6** | D | D | D | D | D | >99 | 56.6 | 23.4 | 11.8 | 5.8 | 2.3 | | **0.7** | D | D | D | D | D | 80.4 | 32.1 | 16.9 | 9.4 | 5.0 | 2.1 | | **0.8** | D | D | D | D | >99 | 42.3 | 22.6 | 13.3 | 7.9 | 4.4 | 1.9 | | **0.9** | D | D | D | >99 | 54.5 | 28.9 | 17.5 | 11.0 | 6.9 | 4.0 | 1.8 | | **1** | D | D | >99 | 69.3 | 36.1 | 22.1 | 14.4 | 9.5 | 6.1 | 3.6 | 1.7 |  1. W\_65\_0\_M |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***W\_65*** | | Specificity | | | | | | | | | | | | ***0\_F*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Sensitivity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | D | >99 | 8.1 | | **0.2** | D | D | D | D | D | D | D | D | >99 | 24.4 | 4.6 | | **0.3** | D | D | D | D | D | D | D | >99 | 39.8 | 12.9 | 3.4 | | **0.4** | D | D | D | D | D | D | >99 | 54.5 | 21.0 | 9.0 | 2.8 | | **0.5** | D | D | D | D | D | >99 | 68.6 | 28.8 | 14.4 | 7.0 | 2.5 | | **0.6** | D | D | D | D | >99 | 82.0 | 36.5 | 19.8 | 11.1 | 5.8 | 2.3 | | **0.7** | D | D | D | >99 | 94.7 | 44.1 | 25.1 | 15.2 | 9.1 | 5.0 | 2.1 | | **0.8** | D | D | >99 | >99 | 51.4 | 30.3 | 19.2 | 12.4 | 7.8 | 4.5 | 2.0 | | **0.9** | D | >99 | >99 | 58.4 | 35.4 | 23.2 | 15.7 | 10.6 | 6.9 | 4.1 | 1.9 | | **1** | >99 | >99 | 65.4 | 40.4 | 27.1 | 18.9 | 13.3 | 9.2 | 6.1 | 3.7 | 1.8 | |
| 1. W\_65\_0\_F |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***R\_50*** | | *Sensitivity* | | | | | | | | | | | | ***0\_M*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Specificity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | D | D | 7.5 | | **0.2** | D | D | D | D | D | D | D | D | D | D | 5.1 | | **0.3** | D | D | D | D | D | D | D | D | D | 38.2 | 4.3 | | **0.4** | D | D | D | D | D | D | D | D | D | 19.0 | 3.9 | | **0.5** | D | D | D | D | D | D | D | D | 82.0 | 13.3 | 3.6 | | **0.6** | D | D | D | D | D | D | D | D | 35.4 | 10.5 | 3.5 | | **0.7** | D | D | D | D | D | D | D | >99 | 23.2 | 8.9 | 3.3 | | **0.8** | D | D | D | D | D | D | D | 54.8 | 17.7 | 7.8 | 3.2 | | **0.9** | D | D | D | D | D | D | >99 | 34.4 | 14.5 | 7.1 | 3.2 | | **1** | D | D | D | D | D | D | 78.5 | 25.5 | 12.4 | 6.5 | 3.1 | |
| 1. R\_50\_0\_M |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***R\_50*** | | *Sensitivity* | | | | | | | | | | | | ***0\_F*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Specificity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | D | D | 7.5 | | **0.2** | D | D | D | D | D | D | D | D | D | D | 5.2 | | **0.3** | D | D | D | D | D | D | D | D | D | 35.2 | 4.4 | | **0.4** | D | D | D | D | D | D | D | D | D | 19.1 | 4.0 | | **0.5** | D | D | D | D | D | D | D | D | 63.0 | 13.7 | 3.8 | | **0.6** | D | D | D | D | D | D | D | D | 32.9 | 11.0 | 3.7 | | **0.7** | D | D | D | D | D | D | D | 90.7 | 22.9 | 9.4 | 3.6 | | **0.8** | D | D | D | D | D | D | D | 46.8 | 17.9 | 8.3 | 3.5 | | **0.9** | D | D | D | D | D | D | >99 | 32.2 | 14.9 | 7.5 | 3.4 | | **1** | D | D | D | D | D | D | 60.7 | 24.8 | 12.9 | 6.9 | 3.4 | |
| 1. R\_50\_0\_F |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***R\_65*** | | *Sensitivity* | | | | | | | | | | | | ***0\_M*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Specificity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | D | >99 | 8.0 | | **0.2** | D | D | D | D | D | D | D | D | >99 | 20.4 | 4.4 | | **0.3** | D | D | D | D | D | D | D | >99 | 31.5 | 10.8 | 3.1 | | **0.4** | D | D | D | D | D | D | >99 | 41.5 | 16.9 | 7.5 | 2.5 | | **0.5** | D | D | D | D | D | >99 | 50.7 | 22.7 | 11.7 | 5.8 | 2.2 | | **0.6** | D | D | D | D | >99 | 59.1 | 28.2 | 15.7 | 9.0 | 4.8 | 1.9 | | **0.7** | D | D | D | >99 | 66.7 | 33.4 | 19.6 | 12.1 | 7.4 | 4.1 | 1.7 | | **0.8** | D | D | >99 | 73.8 | 38.4 | 23.4 | 15.2 | 9.9 | 6.3 | 3.6 | 1.6 | | **0.9** | D | >99 | 80.3 | 43.2 | 27.1 | 18.1 | 12.4 | 8.4 | 5.5 | 3.3 | 1.5 | | **1** | >99 | 86.3 | 47.7 | 30.6 | 21.0 | 14.8 | 10.5 | 7.3 | 4.9 | 3.0 | 1.4 | |
| 1. R\_65\_0\_M |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***R\_65*** | | *Sensitivity* | | | | | | | | | | | | ***0\_F*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Specificity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | D | 77.0 | 7.3 | | **0.2** | D | D | D | D | D | D | D | D | 65.3 | 17.4 | 4.1 | | **0.3** | D | D | D | D | D | D | >99 | 61.4 | 23.9 | 10.1 | 3.0 | | **0.4** | D | D | D | D | D | >99 | 59.5 | 28.4 | 14.8 | 7.3 | 2.4 | | **0.5** | D | D | D | D | >99 | 58.3 | 31.7 | 18.6 | 10.9 | 5.8 | 2.1 | | **0.6** | D | D | >99 | >99 | 57.5 | 34.2 | 21.8 | 14.0 | 8.7 | 4.8 | 1.9 | | **0.7** | D | >99 | >99 | 57.0 | 36.3 | 24.4 | 16.7 | 11.3 | 7.3 | 4.2 | 1.7 | | **0.8** | >99 | 93.2 | 56.6 | 37.9 | 26.6 | 19.0 | 13.6 | 9.5 | 6.3 | 3.7 | 1.6 | | **0.9** | 87.0 | 56.2 | 39.3 | 28.5 | 21.1 | 15.6 | 11.5 | 8.2 | 5.6 | 3.4 | 1.5 | | **1** | 56.0 | 40.4 | 30.1 | 22.9 | 17.5 | 13.3 | 10.0 | 7.3 | 5.0 | 3.1 | 1.5 | |
| 1. R\_65\_0\_F |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***D\_65*** | | *Sensitivity* | | | | | | | | | | | | ***0\_M*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Specificity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | D | 44.1 | 6.8 | | **0.2** | D | D | D | D | D | D | D | >99 | 36.0 | 12.8 | 3.6 | | **0.3** | D | D | D | D | D | >99 | 84.7 | 33.4 | 16.2 | 7.6 | 2.5 | | **0.4** | D | D | D | D | >99 | 62.0 | 32.0 | 18.3 | 10.5 | 5.5 | 1.9 | | **0.5** | D | D | >99 | >99 | 52.3 | 31.2 | 19.8 | 12.7 | 7.9 | 4.3 | 1.6 | | **0.6** | >99 | >99 | 79.3 | 46.9 | 30.7 | 20.9 | 14.4 | 9.8 | 6.3 | 3.6 | 1.4 | | **0.7** | >99 | 66.5 | 43.5 | 30.3 | 21.8 | 15.8 | 11.4 | 8.0 | 5.3 | 3.1 | 1.2 | | **0.8** | 58.8 | 41.1 | 30.0 | 22.4 | 16.9 | 12.7 | 9.4 | 6.7 | 4.5 | 2.7 | 1.1 | | **0.9** | 39.3 | 29.8 | 22.9 | 17.8 | 13.8 | 10.6 | 8.0 | 5.8 | 4.0 | 2.4 | 1.0 | | **1** | 29.6 | 23.4 | 18.6 | 14.8 | 11.7 | 9.2 | 7.0 | 5.2 | 3.6 | 2.2 | 1.0 | |
| 1. D\_65\_0\_M |
| |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ***D\_65*** | | *Sensitivity* | | | | | | | | | | | | ***0\_F*** | | **0** | **0.1** | **0.2** | **0.3** | **0.4** | **0.5** | **0.6** | **0.7** | **0.8** | **0.9** | **1** | | *Specificity* | **0** | D | D | D | D | D | D | D | D | D | D | ∞ | | **0.1** | D | D | D | D | D | D | D | D | >99 | 28.3 | 6.2 | | **0.2** | D | D | D | D | D | >99 | >99 | 46.8 | 23.8 | 11.2 | 3.3 | | **0.3** | D | D | >99 | >99 | 99.6 | 57.0 | 35.4 | 22.2 | 13.4 | 7.1 | 2.4 | | **0.4** | >99 | >99 | 97.7 | 63.5 | 43.6 | 30.6 | 21.5 | 14.7 | 9.5 | 5.3 | 1.9 | | **0.5** | 96.6 | 67.9 | 49.8 | 37.2 | 28.0 | 21.0 | 15.5 | 11.0 | 7.4 | 4.3 | 1.6 | | **0.6** | 54.5 | 42.5 | 33.5 | 26.4 | 20.7 | 16.1 | 12.2 | 8.9 | 6.1 | 3.6 | 1.4 | | **0.7** | 38.1 | 31.0 | 25.3 | 20.5 | 16.5 | 13.0 | 10.1 | 7.5 | 5.2 | 3.1 | 1.3 | | **0.8** | 29.3 | 24.5 | 20.4 | 16.8 | 13.7 | 11.0 | 8.6 | 6.4 | 4.5 | 2.8 | 1.2 | | **0.9** | 23.9 | 20.2 | 17.1 | 14.3 | 11.8 | 9.5 | 7.5 | 5.7 | 4.0 | 2.5 | 1.1 | | **1** | 20.1 | 17.3 | 14.7 | 12.4 | 10.3 | 8.4 | 6.7 | 5.1 | 3.6 | 2.3 | 1.1 | |
| 1. D\_65\_0\_F |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | ***Cause of Death (%)*** | | | ***Average Number of Events*** | | | |
| ***OAC*** | ***Patient population[[2]](#footnote-2)*** | ***Strategy*** | **Life Years** | **Stroke** | **Bleed** | **Other** | **Dependent Strokes** | **Independent Strokes** | **ICH** | **NICH** |
| **Warfarin** | **Male, 50 years old** | **Without TTE** | 28.840 | 11.7 | 1.3 | 87.1 | 0.120 | 0.242 | 0.010 | 0.075 |
| **With TTE** | 28.928 | 10.8 | 1.8 | 87.4 | 0.111 | 0.223 | 0.014 | 0.112 |
| **Female, 50 years old** | **Without TTE** | 31.633 | 13.5 | 1.6 | 84.9 | 0.139 | 0.278 | 0.012 | 0.091 |
| **With TTE** | 31.734 | 12.6 | 2.1 | 85.2 | 0.130 | 0.259 | 0.017 | 0.130 |
| **Male, 65 years old** | **Without TTE** | 17.131 | 9.0 | 0.9 | 90.2 | 0.087 | 0.192 | 0.007 | 0.052 |
| **With TTE** | 17.204 | 8.0 | 1.3 | 90.7 | 0.078 | 0.172 | 0.010 | 0.079 |
| **Female, 65 years old** | **Without TTE** | 19.447 | 10.6 | 1.1 | 88.3 | 0.105 | 0.225 | 0.009 | 0.065 |
| **With TTE** | 19.531 | 9.6 | 1.6 | 88.8 | 0.096 | 0.205 | 0.012 | 0.095 |
| **Rivaroxaban** | **Male, 50 years old** | **Without TTE** | 28.861 | 11.5 | 1.3 | 87.2 | 0.117 | 0.239 | 0.010 | 0.075 |
| **With TTE** | 28.963 | 10.5 | 1.8 | 87.6 | 0.108 | 0.219 | 0.014 | 0.113 |
| **Female, 50 years old** | **Without TTE** | 31.657 | 13.3 | 1.6 | 85.1 | 0.136 | 0.275 | 0.012 | 0.091 |
| **With TTE** | 31.772 | 12.4 | 2.1 | 85.5 | 0.127 | 0.255 | 0.017 | 0.130 |
| **Male, 65 years old** | **Without TTE** | 17.141 | 8.8 | 0.9 | 90.3 | 0.085 | 0.190 | 0.007 | 0.052 |
| **With TTE** | 17.221 | 7.8 | 1.3 | 90.9 | 0.076 | 0.169 | 0.010 | 0.080 |
| **Female, 65 years old** | **Without TTE** | 19.460 | 10.5 | 1.1 | 88.4 | 0.103 | 0.223 | 0.009 | 0.066 |
| **With TTE** | 19.554 | 9.4 | 1.6 | 89.0 | 0.093 | 0.201 | 0.012 | 0.096 |
| **Dabigatran** | **Male, 65 years old** | **Without TTE** | 17.158 | 8.6 | 0.9 | 90.5 | 0.081 | 0.188 | 0.007 | 0.053 |
| **Female, 65 years old** | **With TTE** | 17.251 | 7.5 | 1.3 | 91.2 | 0.072 | 0.163 | 0.010 | 0.081 |

|  |  |
| --- | --- |
| X:\BMJ Echo AF Manuscript\S8\scatter_W_50_M.jpeg | X:\BMJ Echo AF Manuscript\S8\scatter_W_50_F.jpeg |
| a ) Warfarin, 50 years old, males | b) Warfarin, 50 years old, females |

|  |  |
| --- | --- |
| X:\BMJ Echo AF Manuscript\S8\scatter_W_65_M.jpeg | X:\BMJ Echo AF Manuscript\S8\scatter_W_65_F.jpeg |
| c ) Warfarin, 65 years old, males | d) Warfarin, 65 years old, females |

|  |  |
| --- | --- |
| X:\EchoAF\R\Figures\R_50_0_M__PSA.jpeg | X:\EchoAF\R\Figures\R_50_0_F__PSA.jpeg |
| e ) Rivaroxaban, 50 years old, males | f) Rivaroxaban, 50 years old, females |

|  |  |
| --- | --- |
| X:\EchoAF\R\Figures\R_65_0_M__PSA.jpeg | X:\EchoAF\R\Figures\R_65_0_F__PSA.jpeg |
| g ) Rivaroxaban, 65 years old, males | h) Rivaroxaban, 65 years old, females |

|  |  |
| --- | --- |
| X:\EchoAF\R\Figures\D_65_0_M__PSA.jpeg | X:\EchoAF\R\Figures\D_65_0_F__PSA.jpeg |
| i ) Dabigatran 65 years old, males | j) Dabigatran, 65 years old, females |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| OAC | Patient Population | Strategy | Mean Cost (£) | Mean QALY | ICER (95% CrI), £/QALY | TTE dominated? |
| Warfarin | Male, Aged 50 | No TTE | 2459 | 13.60 | -26 489  (-26 552 to -26 408) | Yes |
| TTE | 4712 | 13.51 |
| Female, Aged 50 | No TTE | 2815 | 14.27 | -34 078  (-34 175 to -33 952) | Yes |
| TTE | 5405 | 14.19 |
| Male, Aged 65 | No TTE | 1527 | 9.12 | 66 793  (66 217 to 67 599) | No |
| TTE | 2467 | 9.13 |
| Female, Aged 65 | No TTE | 1974 | 9.94 | 39 485  (39 291 to 39 754) | No |
| TTE | 3106 | 9.97 |
| Rivaroxaban | Male, Aged 50 | No TTE | 2449 | 13.61 | -34 060  (-34 170 to -33 910) | Yes |
| TTE | 4614 | 13.54 |
| Female, Aged 50 | No TTE | 2779 | 14.27 | -47 535  (-47 773 to -47 271) | Yes |
| TTE | 5315 | 14.22 |
| Male, Aged 65 | No TTE | 1510 | 9.12 | 30 310  (30 179 to 30 487) | No |
| TTE | 2393 | 9.15 |
| Female, Aged 65 | No TTE | 1955 | 9.95 | 22 751  (22 681 to 22 844) | No |
| TTE | 3039 | 9.99 |
| Dabigatran | Male, Aged 65 | No TTE | 1487 | 9.13 | 14 728  (14 693 to 14 782) | No |
| TTE | 2321 | 9.18 |
| Female, Aged 65 | No TTE | 1942 | 9.95 | 12 314  (12 290 to 12 348) | No |
| TTE | 2946 | 10.01 |

1. Precise ICER is £30,310/QALY, so the No TTE option is still optimal at £30,000/QALY. [↑](#footnote-ref-1)
2. All populations had initial CHADS2 scores of 0 [↑](#footnote-ref-2)